Form 4: Zevra Therapeutics Legal Chief Sells 24,000 Shares Under Pre-Arranged Plan
Insider Transaction Report
Rahsaan Thompson, Chief Legal & Compliance Secretary of Zevra Therapeutics, Inc., sold 24,000 shares of common stock for approximately $9.21 per share under a Rule 10b5-1 plan.
Summary
- Rahsaan Thompson, Chief Legal & Compliance Secretary of Zevra Therapeutics, Inc. (ZVRA), reported a sale of common stock.
- The transaction occurred on June 26, 2025.
- A total of 24,000 shares were disposed of.
- The shares were sold at a weighted average price of $9.2085 per share, with prices ranging from $9.11 to $9.30.
- Following this transaction, Rahsaan Thompson beneficially owns 42,666 shares of Zevra Therapeutics common stock.
- The sale was executed pursuant to a Rule 10b5-1(c) plan, which was adopted on March 27, 2025.
Sentiment
Score: 4
Explanation: The sale of shares by a key executive, even under a pre-arranged plan, is generally viewed as a neutral to slightly negative signal as it reduces insider alignment with shareholders. The pre-planned nature mitigates some of the negative sentiment.
Negatives
- An insider, the Chief Legal & Compliance Secretary, sold a significant number of shares (24,000 shares).
- The sale reduces the insider's direct ownership in the company, potentially signaling a reduction in alignment with shareholder interests, although it was pre-planned.
Risks
- Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects by those with intimate knowledge.
Industry Context
This transaction is a routine insider trading disclosure for a publicly traded biotechnology or pharmaceutical company, common across all industries when executives manage their personal stock holdings, often through pre-arranged plans.
Stakeholder Impact
- Shareholders may interpret the insider sale as a signal regarding the company's future prospects, potentially influencing their investment decisions.
Key Dates
| Date | Description |
|---|---|
| 03-27-2025 | Adoption date of the Rule 10b5-1(c) plan. |
| 06-26-2025 | Date of the reported transaction (sale of common stock). |
| 06-30-2025 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Zevra Therapeutics, ZVRA, Rahsaan Thompson, SEC Form 4, Insider Trading, Stock Sale, Rule 10b5-1 Plan, Corporate Officer, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.